Atherosclerosis
Volume 195, Issue 1 , Pages 31-38 , November 2007

Differential role and tissue specificity of interleukin-1α gene expression in atherogenesis and lipid metabolism

  • Yehuda Kamari

      Affiliations

    • Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • These authors contributed equally to this work.
    • ,
  • Rachel Werman-Venkert

      Affiliations

    • Department of Microbiology and Immunology, Ben-Gurion University, Beer-Sheva, Israel
    • These authors contributed equally to this work.
    • ,
  • Aviv Shaish

      Affiliations

    • Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • ,
  • Ariel Werman

      Affiliations

    • Department of Microbiology and Immunology, Ben-Gurion University, Beer-Sheva, Israel
    • ,
  • Ayelet Harari

      Affiliations

    • Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • ,
  • Ayelet Gonen

      Affiliations

    • Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • ,
  • Elena Voronov

      Affiliations

    • Department of Microbiology and Immunology, Ben-Gurion University, Beer-Sheva, Israel
    • ,
  • Itamar Grosskopf

      Affiliations

    • Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • ,
  • Yehonatan Sharabi

      Affiliations

    • Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • ,
  • Ehud Grossman

      Affiliations

    • Hypertension Unit, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • ,
  • Yoichiro Iwakura

      Affiliations

    • Center for Experimental Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan
    • ,
  • Charles A. Dinarello

      Affiliations

    • Department of Medicine, University of Colorado Health Science Center, Denver, United States
    • ,
  • Ron N. Apte

      Affiliations

    • Department of Microbiology and Immunology, Ben-Gurion University, Beer-Sheva, Israel
    • These authors contributed equally to this work.
    • ,
  • Dror Harats

      Affiliations

    • Institute of Lipid and Atherosclerosis Research, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Hashomer 52621, Israel
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author. Tel.: +972 3 5302940; fax: +972 3 5343521.

Received 12 July 2006 ,Revised 5 October 2006 ,Accepted 17 November 2006.

References 

  1. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 1998;16:457–499
  2. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618–623
  3. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest. 1986;78:1432–1438
  4. Fantuzzi G, Zheng H, Faggioni R, et al. Effect of endotoxin in IL-1 beta-deficient mice. J Immunol. 1996;157:291–296
  5. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–2147
  6. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990;343:341–346
  7. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest. 1991;88:1445–1451
  8. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2394–2400
  9. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993;261:472–475
  10. Wilasrusmee C, Da Silva M, Singh B, et al. A new in vitro model to study endothelial injury. J Surg Res. 2002;104:131–136
  11. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004;3:330–339
  12. Hacham M, Argov S, White RM, Segal S, Apte RN. Distinct patterns of IL-1 alpha and IL-1 beta organ distribution—a possible basis for organ mechanisms of innate immunity. Adv Exp Med Biol. 2000;479:185–202
  13. Hacham M, Argov S, White RM, Segal S, Apte RN. Different patterns of interleukin-1alpha and interleukin-1beta expression in organs of normal young and old mice. Eur Cytokine Netw. 2002;13:55–65
  14. Werman A, Werman-Venkert R, White R, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA. 2004;101:2434–2439
  15. Nakae S, Naruse-Nakajima C, Sudo K, Horai R, Asano M, Iwakura Y. IL-1 alpha, but not IL-1 beta, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. Int Immunol. 2001;13:1471–1478
  16. Song X, Voronov E, Dvorkin T, et al. Differential Effects of IL-1{alpha} and IL-1{beta} on Tumorigenicity Patterns and Invasiveness. J Immunol. 2003;171:6448–6456
  17. Tamaru M, Tomura K, Sakamoto S, Tezuka K, Tamatani T, Narumi S. Interleukin-1beta induces tissue- and cell type-specific expression of adhesion molecules in vivo. Arterioscler Thromb Vasc Biol. 1998;18:1292–1303
  18. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249–1256
  19. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation. 2004;110:1678–1685
  20. Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004;
  21. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation. 1998;97:242–244
  22. Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA. 2002;99:6280–6285
  23. Merhi-Soussi F, Kwak BR, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005;66:583–593
  24. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656–660
  25. Horai R, Asano M, Sudo K, et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med. 1998;187:1463–1475
  26. Zheng H, Fletcher D, Kozak W, et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity. 1995;3:9–19
  27. Sherer Y, Shaish A, Levkovitz H, et al. Magnesium fortification of drinking water suppresses atherogenesis in male LDL-receptor-deficient mice. Pathobiology. 1999;67:207–213
  28. Isoda K, Sawada S, Ayaori M, et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty-liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem. 2004;
  29. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukoc Biol. 2001;70:163–170
  30. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  31. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109:726–732
  32. Lewis KE, Kirk EA, McDonald TO, et al. Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation. 2004;110:540–545
  33. Chait A, Han CY, Oram JF, Heinecke JW. Thematic review series: The immune system and atherogenesis, Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. J Lipid Res. 2005;46:389–403
  34. Vergnes L, Phan J, Strauss M, Tafuri S, Reue K. Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem. 2003;278:42774–42784
  35. Kaplanski G, Farnarier C, Kaplanski S, et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood. 1994;84:4242–4248
  36. Waehre T, Yndestad A, Smith C, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004;109:1966–1972
  37. Somm E, Henrichot E, Pernin A, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes. 2005;54:3503–3509
  38. Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med. 2003;198:877–888
  39. Ferroni P, Basili S, Vieri M, et al. P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. Haemostasis. 1999;29:277–285

PII: S0021-9150(06)00700-3

doi: 10.1016/j.atherosclerosis.2006.11.026

Atherosclerosis
Volume 195, Issue 1 , Pages 31-38 , November 2007

Article Tools

* Image Usage & Resolution